DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Canadian Multicentre CSF Monitoring and Biomarker Study

Information source: University of British Columbia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Spinal Cord Injury

Intervention: Crossover of vasopressors (Other)

Phase: N/A

Status: Recruiting

Sponsored by: University of British Columbia

Official(s) and/or principal investigator(s):
Brian K. Kwon, MD,PhD,FRCSC, Principal Investigator, Affiliation: University of British Columbia and Vancouver General Hospital

Overall contact:
Daniel Rogers, Phone: 604-827-2451, Email: drogers@rickhanseninstitute.org

Summary

The purpose of this study is to: 1. Measure the pressure in the spinal fluid surrounding the spinal cord to find out how well the spinal cord is being supplied with blood. 2. Determine how drugs called "vasopressors", which are used to control blood pressure following SCI (spinal cord injury), influence spinal fluid pressure. 3. Characterize the severity of an SCI using the levels of specific proteins found within the spinal fluid. 4. Predict how much neurologic recovery may be regained using the levels of specific proteins within your spinal fluid. 5. Identify proteins within the spinal fluid that will help us learn more about what is happening after SCI and assist us in developing new treatments for SCI.

Clinical Details

Official title: The Canadian Multicentre CSF Monitoring and Biomarker Study

Study design: Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Spinal cord perfusion pressure

Secondary outcome:

Levels of specific biochemical markers in the CSF

International Standards for Neurological Classification of Spinal Cord Injury (aka ASIA Examination)

DN4 and other pain questionnaires

Detailed description: This research project consists of two complementary yet distinct initiatives: 1. First, we will prospectively evaluate spinal cord perfusion pressure(SCPP)in patients with acute spinal cord injuries, to provide scientifically-based guidelines on the management of blood pressure during the acute injury phase. 2. Second, we will evaluate cerebrospinal fluid(CSF) samples from these patients with the goal of prospectively validating a series of biochemical markers that correlate with injury severity and predict neurologic outcome. Ultimately, our goals are to enhance the neurologic outcome of individuals with spinal cord injuries by improving upon their acute clinical care, and to establish biological surrogates of injury severity that may be used to facilitate clinical trials of novel therapeutic interventions for acute spinal cord injury. Specific Aims This multicenter study will enroll patients with acute traumatic cervical and thoracic SCI within 48 hours of their injury. A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of intrathecal pressure (ITP) and the collection of CSF samples. Spinal cord perfusion pressure will be calculated as the difference between mean arterial pressure (MAP) and the ITP. The objectives of this aspect of the study will be to:

- Document the changes in SCPP over the first 5-7 days post-injury (with an intrathecal

catheter that is in place for 5 days).

- Determine the effect of different vasopressor agents on SCPP.

Additionally, CSF samples will be obtained from the intrathecal catheter at 8-hour intervals to analyse the expression of the following biochemical markers: including interleukin (IL)-6, IL-8, monocyte chemo-attractant protein (MCP)-1, glial fibrillary acidic protein (GFAP), S100beta, and tau. The objectives of this aspect of the study will be to:

- Evaluate the accuracy of these inflammatory and neuronal markers at classifying the

initial severity of paralysis and at predicting the extent of neurologic recovery.

- Characterize the temporal pattern of expression of these proteins to provide a more

complete description of the human pathophysiology of SCI.

Eligibility

Minimum age: 17 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 17 years of age or older

- Complete (AIS A)or incomplete (AIS B, C) acute SCI involving bony spinal levels

between C0 and L1

- Non-penetrating injury

- Able to communicate in English and provide informed consent

- Enrolled within 48 hours after injury and able to provide CSF and blood samples

within this period Exclusion Criteria:

- SCI that involves sensory impairment only (i. e., no impairment in ability to move

arms and legs)

- Penetrating spinal cord injury

- Isolated radiculopathy (injury only to the nerve outside of the spinal cord)

- Cauda equina injury (injury to nerve roots at the end of the spinal cord)

- Severe injury to head at the time of the SCI

- Injury to lower back (below the spinal level L1)

- Major injury to legs, arms, pelvis, chest, or abdomen that make it impossible for

doctors to tell how severely injured the spinal cord is

- Have a pre-existing neurological disorder such as Parkinson's disease, Alzheimer's

disease, Huntington's disease, or multiple sclerosis or amyotrophic lateral sclerosis.

- Pre-existing thromboembolic disease or coagulopathy (disorders related to blood

clotting), such as haemophilia or von Willebrand's disease

- Pre-existing and ongoing infection in the body (e. g., pneumonia, urinary tract

infection, cellulitis)

- Pre-existing inflammatory or autoimmune disorder such as rheumatoid arthritis,

systemic lupus, psoriasis

- Systemic disease that may interfere with safety or evaluation of the condition we're

studying (e. g., heart disease, HIV, HTLV-1)

- Any other medical condition that in the investigator's opinion would render the study

procedures dangerous or impair ability to receive study therapy

- Receipt of investigational drug within 30 days of injury

- Pregnancy

Locations and Contacts

Daniel Rogers, Phone: 604-827-2451, Email: drogers@rickhanseninstitute.org

Vancouver General Hospital, Vancouver, British Columbia V5Z 1M9, Canada; Recruiting
Brian K. Kwon, MD,PhD,FRCSC, Principal Investigator

QEII Health Sciences Centre, Halifax, Nova Scotia, Canada; Recruiting

Hamilton Health Sciences Centre, Hamilton, Ontario, Canada; Recruiting

London Health Science Centre- Victoria Campus, London, Ontario, Canada; Recruiting

Hôpital du Sacré-Coeur, Montreal, Quebec, Canada; Recruiting

Additional Information

Starting date: January 2011
Last updated: June 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017